IP Library Granted Patent US 11,045,521
Granted Patent B2
US 11,045,521 · App. 16/291,390 · Granted Jun 29, 2021

Therapeutic and cosmetic uses and applications of calreticulin

Inventors: Leslie I. Gold (New York, NY); Marek Michalak (Edmonton, CA)
Assignee: NEW YORK UNIVERSITY
A61K38/1738A61K8/0208A61K8/64A61K8/735A61Q7/00A61Q19/08A61K2800/91
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,045,521
App. No.
16/291,390
Granted
Jun 29, 2021
Kind
B2
Abstract

The invention relates to therapeutic and cosmetic uses of calreticulin including reducing eliminating wrinkles and/or fine lines, tissue repair and reconstruction, repairing damaged and/or cartilage, stimulating regeneration of an epidermal appendage, enhancing phagocytosis of bacteria by phagocytes within a wound, treating a wound in a patient suffering delayed wound healing, treating a corneal wound, and treating or preventing a surgical adhesion.

Claims (9)

1. A method for treating a wound in an eye of a patient in need thereof, which method comprises administering to the wound of the patient a therapeutically effective amount of calreticulin.

2. The method of claim 1 , wherein the wound is a corneal wound.

3. The method of claim 2 , wherein the corneal wound is a corneal abrasion.

4. The method of claim 1 , wherein said calreticulin is administered in an amount ranging between about 5 picogram and about 100 grams.

5. The method of claim 4 , wherein said calreticulin is administered in an amount ranging between about 0.001 milligram and about 50 milligrams.

6. The method of claim 1 , further comprising administering a cytokine, a growth factor, a glycosaminoglycan, a proteoglycan, syndecan, or any mixtures thereof.

7. The method of claim 6 , wherein said glycosaminoglycan is hyaluronic acid.

8. The method of claim 6 , wherein said proteoglycan is perlecan or heparin sulfate.

9. The method of claim 6 , wherein said growth factor is epidermal growth factor.

Assignments (4)
CONFIRMATORY ASSIGNMENT Recorded Jan 10, 2020
From: GOLD, LESLIE I.
To: NEW YORK UNIVERSITY
Reel/Frame 051563/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: GOLD, LESLIE I.
To: NEW YORK UNIVERSITY
Reel/Frame 049337/0776 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: MICHALAK, MAREK
To: CALREGEN INC.
Reel/Frame 049337/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: CALREGEN INC.
To: NEW YORK UNIVERSITY
Reel/Frame 049337/0823 →
Continuity (4)
Division 15004372 · Jan 22, 2016
Division 13717349
Provisional Application 61355987 · Jun 17, 2010
Related Publication 20190343923A1 · Nov 14, 2019